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chemotherapy treatment decision-making. Methods: We embedded the validated 
Decisional Conflict Scale (DCS) into our discrete choice experiment survey exam-
ining preferences for chemotherapy treatment in early BrCa. Of the 1004 general 
population participants, 200 completed the DCS before (DCS-1; no GEP test score 
in scenario) and after (DCS-2; GEP test score added to scenario) the discrete choice 
experiment. The 16-item DCS was scored from 0-100 with five subscores. Mean 
total and subscores, standard deviations and change in scores were calculated, with 
significance based on matched pairs t-tests (p< 0.05). We anticipated GEP would 
decrease decisional conflict in individuals unsure of their chemotherapy treat-
ment decision. Results: As anticipated, total score and all subscores (uncertainty, 
informed, values clarity, support, and effective decision) decreased significantly (all 
p< 0.05) in the group of respondents (n= 33) who indicated uncertainty about tak-
ing chemotherapy in DCS-1 but changed to no chemotherapy after receiving a GEP 
test score in DCS-2. In the group of respondents (n= 25) who indicated they would 
undergo chemotherapy in DCS-1 but changed to unsure in DCS-2, their effective 
decision subscore increase significantly (24.5 to 34.5, p< 0.05). In the overall sample 
(n= 200), total decisional conflict decreased from DCS-1 to DCS-2 by 0.5 (p= 0.3) and 
all subscores had non-significant decreases with the exception of effective deci-
sion, which had a non-significant increase. ConClusions: GEP influences chemo-
therapy treatment decisional conflict in individuals who are initially unsure in their 
treatment decision-making. However, we do not observe this effect in individuals 
who do not change their chemotherapy treatment decisions.
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objeCtives: In oncology, the impact of interventions on health-related quality of life 
(HRQL) is traditionally modelled based on disease progression status. The aim of this 
analysis was to assess if more meaningful patterns exist in HRQL data, based on other 
clinically important events that should be considered in modelling utility. Methods: 
HRQL data from the CA184-024 trial of ipilimumab plus dacarbazine in previously 
untreated patients with unresectable malignant melanoma were analysed. European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 
Core-30 (EORTC QLQ-C30) responses were mapped to a generic, preference-based 
measure (EORTC-8D) by means of a published and validated mapping algorithm. 
The utility observations available for each patient were used to examine the relation-
ships between HRQL and a number of disease- and time-based variables, including 
treatment effect, progression status and time to death, via a mixed effects regression 
model. Results: Progression status was found not to be significantly predictive of 
utility (p= 0.29). Of the variables considered, the strongest relationship was with time 
to death, the mixed effects model for which was significantly predictive of utility 
(p≤ 0.001). HRQL dropped as patients approached death; patients treated with ipili-
mumab had a utility of 0.86 if time to death was more than 1 year, which reduced to 
0.61 during the final month of life. The ipilimumab treatment variable was associated 
with a small negative coefficient (-0.02), accounting for the adverse event profile of the 
drug when added to dacarbazine (p= 0.06). ConClusions: Analysis of the CA184-024 
HRQL data showed that time to death rather than progression status was significantly 
predictive of utility. Hence, modellers should carefully examine primary data to deter-
mine if a time to event approach or a progression based approach is appropriate to 
model utility best reflecting the pathology of the disease.
PRM149
RascH FiRst? FactoR FiRst?
Chen W.H., McLeod L.D., Coles T.M.
RTI Health Solutions, Research Triangle Park, NC, USA
objeCtives: Rasch modelling theory and its extensions have become popular tools 
in assessing psychometric properties of patient-reportedoutcome (PRO) instru-
ments. Since the Rasch model assumes a unidimensional structure, it is important 
to assert that this assumption has not been violated. However, there has been much 
debate about using factor analysis as the first step to assess dimensionality or using 
the Rasch model directly to identify items not fitting the unidimensional model. 
This study uses simulated data to compare the two techniques to examine the uni-
dimensional assumptions.  Methods: Simulated data that represent a typical PRO 
instrument are generated based on the following variables: sample size (200 or 400), 
number of factors (1,2, or 3), and correlation among factors (0.4 or 0.7). Each simu-
lated PRO assessment contains 15 items with 5 response categories. Exploratory 
factor analysis is conducted, and the number of factors proposed by the results 
are noted. A Rasch model theory analysis is also conducted, and the number of 
mis-fit items is noted. The unidimensional test associated with Rasch model is also 
conducted. Results: Preliminary results suggest that when there is one dominant 
factor, the Rasch results identify the simulated factor and it becomes the underlying 
trait. Items not belonging to the dominant factor are flagged as mis-fit items or as 
forming secondary factors based on the unidimensional test. In situations where 
there is no dominant factor, factor analysis is able to identify separate factors, 
whereas the results are inconsistent using Rasch model. ConClusions: Rasch first 
or factor first? The preliminary findings suggest that, when there is prior knowledge 
of a dominant factor, Rasch modelling can be conducted first and will result in a 
unidimensional measure. When there is no prior knowledge of a dominant fac-
tor, then factor analysis should be conducted first to examine the dimensionality.
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(> 0.7) for the Physical domain, high (> 0.5) for the Total score and the Living domain 
and moderate (> 0.3) for the Cognition and Emotional domains. ConClusions: The 
BRAF-MDQ was completed well by participants, related to appropriate measures 
of disease severity, retained its factor structure, gave reproducible results and was 
responsive to clinical change, confirming its validity as a measure of RA fatigue.
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objeCtives: Patient-reported outcome (PRO) measures provide relevant information 
on how patients function and feel about their health. Such data are useful in clinical 
practice and registrational trials. Despite the importance of symptom assessment in 
CDAD, there is no validated PRO for Clostridium difficile-associated diarrhoea (CDAD). 
A qualitative research study was conducted to develop a CDAD PRO according to US 
FDA PRO guidelines. Methods: Content development comprised 2 study phases, 
with input from an advisory group of 6 CDAD experts in Europe and North America. 
Phase I elicited patients’ experiences of CDAD symptoms in open-ended discussions 
during telephone interviews. Supplementary interviews obtained nurses’ observa-
tions. A draft PRO was developed following demonstration of concept saturation. 
Readability and translatability were assessed. Phase II involved 2 rounds of patient 
interviews, with revision of the draft PRO after each round. All patients were ≥ 18 
years old, with confirmed CDAD. IRB approval and participant informed consent 
were obtained. Results: Phase I interviews included 18 patients and 6 nurses in 
the United States; 16 additional patients were interviewed in Phase II. Patients were 
representative of the general CDAD population, and diverse in age, gender, and disease 
severity. Concept saturation was reached in Phase I for spontaneously reported CDAD 
symptoms. Items were organised in a draft conceptual framework with 5 hypoth-
esised domains: diarrhoea, abdominal discomfort, tiredness, lightheadedness, and 
other symptoms. Phase II demonstrated initial content validity of the 13-item draft 
daily diary (CDAD-DaySyms™). Participants reported the questions were clear, rel-
evant, and comprehensive; were able to use the instructions to complete the diary 
correctly; and considered the 24-hour recall period appropriate. ConClusions: 
The CDAD-DaySyms™ captures symptoms relevant to CDAD patients, demonstrat-
ing initial content validity. To allow its use in clinical practice and CDAD clinical 
studies, final content and psychometric validity are being evaluated in 2 ongoing 
international clinical trials.
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objeCtives: In phase II studies, alirocumab, a PCSK9 inhibitor administered via sub-
cutaneous injection, demonstrated significant reduction in LDL-C levels. The objective 
of this study was to conduct qualitative research to explore the concept of treatment 
acceptance in patients receiving a subcutaneous injection to support the develop-
ment and testing of a patient-reported outcome measure, the Injection-Treatment 
Acceptance Questionnaire (I-TAQ). Methods: A literature review led to the targeting 
of ‘treatment acceptance’ as the measurement concept in preference to treatment 
satisfaction. Concepts generated from the literature and instrument review informed 
the drafting of 17 items in the I-TAQ; item wording was adapted from three validated 
instruments. Qualitative interviews were conducted among 29 US-English speaking 
patients participating in alirocumab’s phase III program who self-administered the 
treatment via autoinjector (n= 19) or pre-filled syringe (n= 10). First, concept elicitation 
(CE) questioning was used to elicit concepts relating to patients’ treatment experi-
ences and acceptance. The I-TAQ was then cognitively debriefed using “think-aloud” 
methods. Verbatim transcripts were analyzed using thematic analysis and Atlas. ti. 
Revisions were considered after each round of interviews. Results: Qualitative 
analysis of CE data indicated treatment acceptance to be high, with the following 
concepts identified as relevant: perceived efficacy, side effects, self-efficacy, conveni-
ence and overall acceptance. Ten (34%) patients reported an initial fear of needles, 
which subsided with no impact on discontinuation. Pain was not considered rel-
evant by patients, suggesting no pain associated with the injection. Five items were 
added following round 1 interviews, three were retained after round 2 testing and two 
were added at finalization, forming the conceptually comprehensive 22-item I-TAQ. 
Patients demonstrated good understanding of item wording, instructions, response 
scales and recall period. ConClusions: Successive rounds of interviews resulted in a 
treatment acceptance measure with strong content validity. Next steps are to psycho-
metrically validate the I-TAQ in a population with experience of taking alirocumab.
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objeCtives: Individuals with BrCa have high decisional conflict with respect to 
treatment decisions. GEP of tumours informs risk prediction, potentially affecting 
decisions about adjuvant chemotherapy in early BrCa, where only 15% will experi-
ence recurrence. We aimed to examine whether GEP reduces decisional conflict in 
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Annual risk of ONJ was the least important attribute. ConClusions: When making 
treatment decisions regarding choice of BTA for patients with bone metastases, the 
main treatment goals for Turkish physicians are reducing risk of renal impairment 
and delaying first SRE.
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objeCtives: To assess EQ-5D-5L validity in patients with acute stroke, in com-
parison to EQ-5D-3L, EQ VAS, modified Rankin Scale (mRS) and Barthel Index 
(BI). Methods: Cross-sectional study of 408 patients (51.5% males; mean age 69 
years), after median 8 days from stroke onset. We assessed: construct validity in 
terms of known-groups validity, convergent validity of EQ-5D-5L dimensions with 
other stroke outcome measures, and criterion-related validity in terms of concur-
rent validity, with mRS as a gold standard. Results: A total of 2.9% EQ-5D-5L and 
3.7% EQ-5D-3L questionnaires had at least one missing answer, indicating good 
feasibility of both instruments in patients with stroke. The proportion of patients 
reporting ‘no problems’ was 38.2% for BI, 6.1% for EQ-5D-3L, 5.6% for EQ-5D-5L, 
5.0% for mRS and 2.5% for EQ VAS. Results of the known-groups validity tests con-
firmed prior hypotheses: health state utilities were lower in females, patients with 
high mRS score, low BI or VAS score, patients with subarachnoid hemorrhage or 
intracerebral hemorrhage, and when proxy respondent was used. Convergence of 
EQ-5D-5L dimensions with mRS, BI and EQ VAS was improved or at least the same 
as EQ-5D-3L dimensions. For predicting outcome in patients with stroke, the sum 
of mRS related EQ-5D-5L dimensions (Mobility, Self-care, Usual activities), gave 1% 
of false positive and 0% of false negative results. ConClusions: Results support 
the validity of the EQ-5D-5L descriptive system as a generic measure assessed by 
self-report and proxy in patients with acute stroke, demonstrating some psycho-
metric advantages in comparison to EQ-5D-3L and substantially lower ceiling effect 
in comparison to Barthel Index.
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objeCtives: EQ-5D has been widely used to measure health status in a variety of 
conditions and the amount of evidence of its performance has increased over recent 
years. The aim of this study was to consolidate this evidence by reviewing papers 
reporting systematic reviews of the psychometric properties (validity and reliability) 
and/or responsiveness of EQ-5D. Methods: Medline and Embase were searched 
for systematic reviews of the performance of EQ-5D. Supplementary searches were 
carried out in Cochrane Library, Web of Science, reference lists of included studies, 
the EuroQol database and hand searching of EuroQol Scientific Plenary Proceedings. 
In addition the website of the Oxford Patient Reported Outcome Measures (PROMs) 
Group was searched for reports. Data were extracted using a template designed 
specifically for the study. Results: 25 reviews were identified in this study and a 
further 18 were identified from the Oxford PROMs group website. The majority of 
studies focussed on adults. Overall there was evidence of good to fair performance 
of EQ-5D in depression, diabetes (type 2), rheumatoid arthritis, skin conditions, can-
cer, cardiovascular disease, asthma, personality disorder and urinary incontinence. 
Evidence was mixed in COPD, dementia, schizophrenia and vision disorders, and 
poor for hearing disorders. The was little evidence for liver transplantation, venous 
leg ulcers, haemophilia, bipolar disorder and low back pain; although limited, the 
evidence showed positive results for liver transplantation, haemophilia and leg 
ulcers. No evidence was identified for, among others, skin cancer and systemic lupus 
erythematous. ConClusions: This study has provided a comprehensive overview 
of the evidence of the performance of EQ-5D. Most evidence suggests good psycho-
metric properties of EQ-5D; however there are particular concerns about its ability 
to capture the impact of dementia, schizophrenia, visual impairment and hearing 
disorders. Further research is encouraged in conditions where data or reviews of 
psychometric properties of EQ-5D are lacking.
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objeCtives: To investigate health-related quality of life (HRQoL) in Italian 
patients with moderate and severe Crohn’s disease (CD) (Harvey Bradshaw 
Index> 8). Methods: EuroQoL 5-dimension 3-level (EQ-5D-3L) questionnaire 
and visual analogue scale (VAS) were administered to 540 consecutive patients 
with moderate and severe CD who referred to a convenience sample of 38 Italian 
inflammatory bowel disease centres (21 teaching-hospitals; 4 research hospitals; 
8 self-governing hospitals; 3 Local Health Authority hospitals; 2 private hospi-
tals) participating in the ongoing Survey on Quality of life in Crohn’s Patients (SOLE) 
objeCtives: Currently no measure can identify, with a high degree of positive pre-
dictive power, suicidal behavior. Because suicide occurs at a low base-rate, studies 
of instruments designed to predict this outcome often lack an adequate sample 
size to prove the tool’s predictive ability. Our aim is to identify an assessment with 
the most promise of predicting suicidal behavior in veteran or military patients and 
present options to overcome previous research hurdles. Methods: Two systematic 
reviews, one performed for the US Department of Veterans [1], and the other as 
part of NICE guidance development [2] provided the background for our analy-
sis. These summaries were reviewed to identify the most predictive assessments 
yet developed. Sensitivity, specificity, positive and negative predictive power were 
tabulated for all reported instruments. Study limitations were recorded along with 
these results. Results: One instrument showed promise of meeting the objec-
tive. The Affective States Questionnaire (ASQ) was able to predict suicide within 3 
months with a sensitivity of 60%, specificity of 74% and positive predictive power 
of 32% [3]. The study that produced those results was performed on an inpatient 
and outpatient veteran population. However, the sample was small with only 283 
patients and the risk of bias was unclear. A larger study may provide the needed 
evidence to make the Affective States Questionnaire a useful screening tool. We 
propose the Affective States Questionnaire be transferred to electronic administra-
tion and provided as part of routine admissions at VA facilities. Deploying the tool 
electronically could provide the large sample sizes required to detect effects on this 
low base-rate outcome. ConClusions: The Affective States Questionnaire shows 
promise of becoming an appropriate screening tool for suicide in a military popu-
lation. Electronic capture may allow for large scale deployment, therefore gaining 
sufficient sample to determine applicability as a screening tool.
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objeCtives: To evaluate psychometric properties of the revised Self-Injection 
Assessment Questionnaire in rheumatoid arthritis patients (pts) receiving certoli-
zumab pegol. Methods: In the study (NCT00674362), pts with low to moderate 
rheumatoid arthritis (RA) received certolizumab pegol (CZP; 400mg at Weeks [Wks] 
0, 2, 4, then 200mg every other wk). In the open-label extension (OLE; NCT00843778), 
pts could self-administer CZP using a pre-filled syringe. Pts in OLE completed the 
revised Self-Injection Assessment Questionnaire (SIAQv2.0
©) at Wks 0, 2, 4, 6, 8, 10, 12. 
Domain scores were calculated per authors’ recommendations, and internal consist-
ency was assessed using the Cronbach’s alpha statistics. Floor and ceiling effects 
were reported as % pts with the worst/best domain score. Construct validity was 
assessed by confirmatory factor analysis fitting the current conceptual framework 
of the questionnaire and by calculating the Bentler’s Comparative Fit Index (CFI) 
and the root mean square error of approximation (RMSEA). Results: 86 pts (mean 
age: 50.8 years; disease duration: 4.6 years) entered the OLE and completed the SIAQ 
at least once. At first self-injection visit, DAS28 (ESR) was 4.0 and HAQ-DI 0.9. The 
internal consistency of all domains was > 0.8 at any visit. Floor effect was < 5% at any 
visit; ceiling effect was ≤ 13% for Self-Confidence, Ease of Use (EU) and Satisfaction 
domains, but reached 40% for Feeling and Injection-Site Reactions domains. The 
ceiling effect of the EU domain was lower (10%) than the original validation (22%). 
The conceptual framework structure was supported by the confirmatory factor 
analysis with CFI values of 0.75–0.86 and RMSEA values of 0.10–0.13, which, given 
the limited sample size, would indicate reasonable goodness of fit. ConClusions: 
Modifications brought to the SIAQv2.0
© appeared to remediate the acquiescence 
bias issue that was noted during the validation of SIAQv1. The appropriateness 
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objeCtives: To evaluate Turkish physicians’ preferences when selecting 
between the different bone-targeted agents (BTAs) available for preventing skel-
etal-related events (SREs) in patients with bone metastases from advanced solid 
tumors. Methods: Physicians from several centres, currently treating patients with 
bone metastases from solid tumours were recruited by phone or personal invitation 
and then engaged in a face-to-face interview where they completed a web-ena-
bled discrete-choice experiment survey. Each survey included 10 choices between 
pairs of hypothetical treatment profiles for the two putative patient profiles. The 
hypothetical treatment profiles included five attributes within a pre-defined range 
(based on prescribing information): time until first SRE (10, 18 and 28 months); time 
until worsening of pain (3, 6 and 10 months); annual risk of osteonecrosis of the 
jaw (ONJ; 0, 1 and 5%); annual risk of renal impairment (0,4 and 10%); and mode 
of administration (oral tablet, subcutaneous injection, 15-minute or 120-minute 
intravenous infusion). Choice questions were based on an experimental design 
with known statistical properties. A main-effects random parameters logit model 
was estimated. Results: A total of 105 physicians agreed to participate in the 
face-to-face interview and accessed the online survey. Of these, 104 physicians 
were eligible and consented to participate and 99 were included in the analysis. 
Estimated preference weights for all applicable attributes were consistent with the 
natural ordering of the categories. Risk of renal impairment and months until first 
SRE were the most important attributes influencing physicians’ decisions, with 
better clinical outcomes preferred to worse outcomes. Preventing pain progres-
sion was the third most important attribute followed by mode of administration. 
